Status:
UNKNOWN
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
Lead Sponsor:
Shandong University
Conditions:
Antineoplastic Adverse Reaction
Thrombocytopenia
Eligibility:
All Genders
15-75 years
Phase:
PHASE3
Brief Summary
Chemotherapy-related myelosuppression usually occurs in AML patients, which induces severe thrombocytopenia and haemorrhage, a leading cause of death. This clinical trial aims at evaluating efficacy a...
Detailed Description
The investigators are undertaking a parallel group, multicentre, randomized controlled trial of 80 adults with chemotherapy-induced thrombocytopenia from 8 medical centers in China. AML patients with ...
Eligibility Criteria
Inclusion
- AML patients with PLT count \<30×10\^9/L during the previous cycle of chemotherapy to minimize the risk of clinically significant bleeding.
Exclusion
- allergic history to biological agents; history of thrombotic or hemorrhagic diseases; M3 or M7 subtype; pregnancy; hypertension; cardiovascular disease; diabetes; liver and kidney function impairment;
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2017
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT02244658
Start Date
September 1 2014
End Date
August 1 2017
Last Update
April 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hospital, Shandong University
Jinan, Shandong, China, 250012